Sanofi Unit Touts Long-Term Drug Efficacy
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study showing sustained benefits and long-term safety for its drug AYVAKIT®. The drug is used to treat indolent systemic mastocytosis, a rare blood disorder.
AYVAKIT, with the generic name avapritinib, functions as a kinase inhibitor. It is designed to selectively target the KIT D816V mutation, which is the primary underlying driver of the disease in the vast majority of patients. Indolent systemic mastocytosis is a rare, chronic blood disease characterized by the overproduction of mast cells, which can cause debilitating symptoms like severe itching, skin lesions, abdominal pain, and fatigue. The prevalence in Europe is estimated to be between 1 in 7,700 and 1 in 10,400 people. The U.S. Food and Drug Administration (FDA) approved AYVAKIT for adults with indolent systemic mastocytosis in May 2023. This followed earlier approvals for advanced systemic mastocytosis in June 2021 and for certain types of gastrointestinal stromal tumors (GIST) in January 2020. The approval for this indication was based on the Phase 2 PIONEER trial, the largest study ever conducted for this disease. The primary endpoint was a significant reduction in the total symptom score for patients treated with AYVAKIT compared to a placebo. The treatment marks a shift in the therapeutic approach from merely supportive care to a disease-modifying therapy that targets the root genetic cause of the illness. Financially, Blueprint Medicines reported $479 million in global net product revenues for AYVAKIT in 2024. The company raised its 2025 revenue guidance to a range of $700 million to $720 million.
